<DOC>
	<DOCNO>NCT00003031</DOCNO>
	<brief_summary>RATIONALE : Antifungal therapy voriconazole amphotericin B may effective treatment aspergillosis . It yet know whether voriconazole effective amphotericin B treating patient aspergillosis . PURPOSE : Randomized phase III trial compare effectiveness voriconazole amphotericin B treating patient aspergillosis .</brief_summary>
	<brief_title>Comparison Voriconazole Amphotericin B Treating Patients With Aspergillosis</brief_title>
	<detailed_description>OBJECTIVES : I . Compare efficacy , safety , toleration voriconazole versus amphotericin B ( CAB ) treatment acute invasive aspergillosis immunocompromised patient . II . Compare efficacy , safety , toleration voriconazole versus CAB follow antifungal therapy treatment acute invasive aspergillosis immunocompromised patient . III . Compare survival patient treat voriconazole versus CAB without antifungal therapy . IV . Investigate resource utilization patient treat voriconazole versus CAB without antifungal therapy . OUTLINE : This open label , randomize , multicenter study . Patients stratify accord center , site infection , underlie disease , baseline neutrophil count . Patients randomize one two treatment arm . Arm I : Patients receive voriconazole IV every 12 hour 7-28 day continue oral voriconazole twice day maximum total duration 12 week therapy . Arm II : Patients receive intravenous amphotericin B daily least 2 week ; treatment continue maximum 12 week . Patients discontinue study drug treatment toxicity , intolerance clinical failure may receive alternative ( nonstudy ) antifungal therapy . All patient monitor total 16 week . PROJECTED ACCRUAL : A sufficient number patient accrue 212 patient ( 106 per study arm ) eligible study .</detailed_description>
	<mesh_term>Aspergillosis</mesh_term>
	<mesh_term>Voriconazole</mesh_term>
	<mesh_term>Amphotericin B</mesh_term>
	<mesh_term>Liposomal amphotericin B</mesh_term>
	<mesh_term>Amphotericin B , deoxycholate drug combination</mesh_term>
	<mesh_term>Deoxycholic Acid</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Patient immunocompromised result following : Allogeneic bone marrow/peripheral stem cell transplant Autologous bone marrow/peripheral stem cell transplant Hematological malignancy ( include lymphoma ) Aplastic anemia myelodysplastic syndrome ( currently immunosuppressive treatment ) Solid organ transplantation ( lung ) Other solid organ malignancy ( cytotoxic chemotherapy ) HIV/AIDS High dose prolong corticosteroid therapy ( least 20 mg/day prednisolone equivalent 3 week ) prolong therapy immunosuppressive agent ( e.g. , azathioprine , methotrexate ) Diagnosis either definite probable acute invasive aspergillosis Fungal infection represent new episode acute invasive aspergillosis Patients follow ineligible : Aspergilloma allergic bronchopulmonary aspergillosis Chronic invasive aspergillosis Sarcoidosis CMV pneumonia PATIENT CHARACTERISTICS : Age : 12 Life expectancy : At least 72 hour Hematopoietic : Not specify Hepatic : Bilirubin great 5 time upper limit normal ( ULN ) SGOT/SGPT great 5 time ULN Alkaline phosphatase great 5 time ULN Renal : Creatinine great 2.5 mg/dL Other : No history hypersensitivity intolerance azole antifungal agent include miconazole , ketoconazole , fluconazole , itraconazole No history hypersensitivity severe intolerance conventional lipid formulation amphotericin B Not pregnant nursing Fertile woman must use effective contraception Negative pregnancy test No prior participation trial Not artificial ventilation unlikely extubated within 24 hour No condition could affect patient safety , preclude evaluation response , make study completion unlikely PRIOR CONCURRENT THERAPY : At least 8 week since prior systemic treatment amphotericin B itraconazole At least 2 week since prior systemic antifungal therapy 96 hour dose great 0.5 mg/kg/day conventional lipid formulation amphotericin B great 200 mg/day itraconazole No concurrent drug metabolize primarily hepatic cytochrome P450 enzymes induce inhibit enzyme , terfenadine , loratidine , astemizole , midazolam , triazolam , cisapride , rifampin , rifabutin , barbiturate , carbamazepine , coumarins , sulfonylurea , nivarapine , erythromycin , ritonavir , delaviridine , omeprazole , phenytoin At least 2 week since prior rifampin , rifabutin , carbamazepine , barbiturates 3 day No concurrent investigational drug cytotoxics , antiretroviral agent , therapy AIDSrelated opportunistic infection No concurrent filgrastim ( GCSF ) sargramostim ( GMCSF ) treatment granulocytopenia No concurrent white blood cell transfusions No concurrent systemic antifungal agent active Aspergillus spp . ( e.g. , itraconazole , lipid formulation amphotericin B , flucytosine )</criteria>
	<gender>All</gender>
	<minimum_age>12 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2012</verification_date>
	<keyword>infection</keyword>
	<keyword>pulmonary complication</keyword>
</DOC>